How Much Dividend Does Leap Therapeutics Inc. (LPTX) Pay?


Leap Therapeutics Inc. (NASDAQ:LPTX) traded with a subtraction of $0.0 to close at $0.44 on Friday, an upside of 1.59 percent. An average of 734,139 shares of common stock have been traded in the last five days. There was a fall of -$0.0099 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 585,320 shares traded, while the 50-day average volume stands at 617,972.

LPTX stock has decreased by -21.19% in the last month. The company shares reached their 1-month lowest point of $0.4000 on 12/28/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $0.40 and a high of $3.45 in 52 weeks. It has reached a new high 1 time so far this year and lost -86.57% or -$2.7899 in price. In spite of this, the price is down -87.18% from the 52-week high.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Valuation Metrics

Leap Therapeutics Inc. (LPTX) stock’s beta is 0.59. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 105.31, the price-to-book (PB) ratio at 0.70.

Financial Health

The quick ratio of Leap Therapeutics Inc. for the three months ended September 29 was 6.80, and the current ratio was 6.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending September 29. Its gross profit as reported stood at $42.93 million compared to revenue of $1.5 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Leap Therapeutics Inc.’s return on assets was -53.30%.

Earnings Surprise

The company posted a net income of -$15.09 million in the quarter, while revenues were grew 26.18%. The analyst consensus anticipated Leap Therapeutics Inc.’s latest quarter earnings to come in at -$0.12 per share, but it turned out to be -$0.13, a -8.30% surprise. For the quarter, EBITDA amounted to -$15.28 million. Shareholders own equity worth $99.02 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Leap Therapeutics Inc. (LPTX) price momentum. RSI 9-day as of the close on 29 December was 42.57%, suggesting the stock is Neutral, with historical volatility in this time frame at 74.18%.

As of today, LPTX’s price is $0.4417 -2.15% or -$0.0099 from its 5-day moving average. LPTX is currently trading -21.79% lower than its 20-day SMA and -58.71% lower than its 100-day SMA. However, the stock’s current price level is -47.32% below the SMA50 and -74.85% below the SMA200.

The stochastic %K and %D were 27.23% and 22.51%, respectively, and the average true range (ATR) was 0.0505. With the 14-day stochastic at 38.87% and the average true range at 0.0535, the RSI (14) stands at 39.01%. The stock has reached -0.0097 on the 9-day MACD Oscillator while the 14-day reading was at -0.0254.

Analyst Ratings

Mizuho launched coverage on Leap Therapeutics Inc. (NASDAQ: LPTX) in its analyst report released on October 04, 2021. The firm assigned the stock a Buy rating. The consensus rating for Leap Therapeutics Inc. (LPTX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell LPTX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 3 others rate it as a “buy”.

What is LPTX’s price target for the next 12 months?

Analysts predict a range of price targets between $2.50 and $6.00, with a median target of $4.00. Taking a look at these predictions, the average price target given by analysts for Leap Therapeutics Inc. (LPTX) stock is $4.10.


Please enter your comment!
Please enter your name here